SPORTS

Spain's Verdasco receives two-month doping ban

November 30, 2022 19:45 IST

IMAGE: Fernando Verdasco admitted the Anti-Doping Rule Violation and said he was diagnosed with attention-deficit/hyperactivity disorder and used methylphenidate as prescribed by his doctor. Photograph: Thomas Peter/Reuters

Spain's Fernando Verdasco has been provisionally suspended for two months after failing to renew a Therapeutic Use Exemption (TUE) and testing positive for the drug methylphenidate, the International Tennis Integrity Agency (ITIA) said on Wednesday.

The 39-year-old, who reached a career-high ranking of number seven in 2009, accepted a voluntary ban until Jan. 8 next year after his urine sample collected at an ATP Challenger event in Rio de Janeiro in February contained the drug.

 

Verdasco admitted the Anti-Doping Rule Violation and said he was diagnosed with attention-deficit/hyperactivity disorder and used methylphenidate as prescribed by his doctor to treat the condition in accordance with a TUE.

However, he forgot to renew the TUE when it expired and has since been given a new one by the World Anti-Doping Agency for his medication moving forwards.

"The ITIA accepts that the player did not intend to cheat, that his violation was inadvertent and unintentional, and that he bears no significant fault or negligence for it," the ITIA said in a statement.

"In the specific circumstances of this case, based on the player's degree of fault the Tennis Anti-Doping Programme allows for the applicable period of ineligibility to be reduced from two years to two months."

Source: REUTERS
© Copyright 2024 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Recommended by Rediff.com

NEXT ARTICLE

NewsBusinessMoviesSportsCricketGet AheadDiscussionLabsMyPageVideosCompany Email